Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03519347 · ClinicalTrials.gov registry record · NA

Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A

A NA study, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
19
Enrollment target

NCT03519347: Completed NA study, sponsored by NYU Langone Health.

NCT03519347 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03519347, a NA study, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
19 participants
Enrollment target

Study Summary

The primary purpose of this study is to test the feasibility of trials which change the dialysate (dialysis bath prescription) of potassium and bicarbonate according to a standardized algorithm and according to the results of blood testing performed prior to each dialysis. In addition, the trial will provide estimates of the extent to which performing dialysis in this way lowers the risk of abnormal heart rhythms in people with kidney failure who are being treated with chronic hemodialysis.

Primary Outcome

Adherence will be assessed as the percent of sessions in which POC testing is completed and the dialysate is adjusted according to the algorithm.

Interventions

  • OTHER Potassium Removal Maximization
  • OTHER Potassium Gradient Minimization
  • OTHER Alkalosis Avoidance
  • OTHER Acidosis avoidance
  • DIAGNOSTIC_TEST Point of Care Testing

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2018-11-30
Est. Completion 2022-10-14
Phase NA
NYU Langone Health

1,164 total trials

What the finished NCT03519347 record still lists

NCT03519347 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 5 interventions - of which Potassium Removal Maximization is the first listed.

NCT03519347 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03519347 about?

NCT03519347 is a clinical study titled "Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A". The primary purpose of this study is to test the feasibility of trials which change the dialysate (dialysis bath prescription) of potassium and bicarbonate according to a standardized algorithm and according to the results of blood testing performed prior to each dialysis. In addition, the trial wil...

What is the current status of trial NCT03519347?

This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2018-11-30. Estimated completion is 2022-10-14.

What interventions are being tested in trial NCT03519347?

The interventions under investigation include: Potassium Removal Maximization (OTHER), Potassium Gradient Minimization (OTHER), Alkalosis Avoidance (OTHER), Acidosis avoidance (OTHER), Point of Care Testing (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03519347?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03519347's enrollment target sits among peer trials

19 1861st of 2000 higher than 138 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03519347, the US trial registry maintained by the National Library of Medicine. NCT03519347 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.